Gregorio J. Petrirena

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity.

Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity.

Journal: Leukemia & lymphoma

Published: March 23, 2026

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Case report of adult-type diffuse high-grade glioma IDH-wildtype subtype E with secondary spinal leptomeningeal dissemination, prolonged survival and literature review.

Journal: Discover oncology

Published: November 24, 2025

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Journal: Journal of neuro-oncology

Published: August 26, 2025

Movement disorders due to primary central nervous system lymphoma: An illustrative case and systematic literature review.

Movement disorders due to primary central nervous system lymphoma: An illustrative case and systematic literature review.

Journal: Revue neurologique

Published: July 29, 2025

Evaluation of MYD88 p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system.

Evaluation of MYD88 p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system.

Journal: British journal of haematology

Published: February 09, 2025

Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.

Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.

Journal: Anticancer research

Published: July 31, 2024

Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GBM).

Radio-chemotherapy feasibility for biopsy-only unresectable IDH wild-type glioblastomas (BO-GBM).

Journal: Neuro-oncology practice

Published: November 27, 2023

Prognostic value of Beta 2-Microglobulinin in cerebrospinal fluid in primary central nervous system lymphoma.

Prognostic value of Beta 2-Microglobulinin in cerebrospinal fluid in primary central nervous system lymphoma.

Journal: Journal of the neurological sciences

Published: August 25, 2023

Primary central nervous system lymphoma with initial spinal cord involvement (PCNSL-SC) is a rare entity: 4 case reports and review of literature.

Primary central nervous system lymphoma with initial spinal cord involvement (PCNSL-SC) is a rare entity: 4 case reports and review of literature.

Journal: Revue neurologique

Published: August 07, 2023

Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma.

Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma.

Journal: Journal of neuro-oncology

Published: April 11, 2022

Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.

Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.

Journal: Journal of neuro-oncology

Published: November 15, 2021

RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases.

RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases.

Journal: Neuro-oncology advances

Published: July 10, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026